Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets

Transfusion

Volumn 55, Issue 6, 2015, Pages 1320-1326

  Scharbert, Gisela ^a   Wetzel, Leonore ^a   Schrottmaier, Waltraud C ^a   Kral, Julia B ^a   Weber, Thomas ^a   Assinger, Alice ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PADGEM PROTEIN; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HEMATOLOGY ANALYZER; HUMAN; INVESTIGATIVE PROCEDURES; LIGHT TRANSMISSION AGGREGOMETRY; LOW DRUG DOSE; MALE; MEASUREMENT; MEDICATION COMPLIANCE; MULTIPLE ELECTRODE AGGREGOMETRY; POTENTIAL DIFFERENCE; PROTHROMBIN TIME; SURFACE PROPERTY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; HALF LIFE TIME; MIDDLE AGED; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION;

ADENOSINE; ADENOSINE DIPHOSPHATE; AGED; BLOOD PLATELETS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE;

EID: 84930871227     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12977     Document Type: Article

References (21)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
4. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66:487-96.
5. Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514-21.
6. th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012;141:e89S-119S.
7. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-44.
8. Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007; 370:427-38.
9. Assinger A, Kral JB, Yaiw KC, et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. Arterioscler Thromb Vasc Biol 2014;34: 801-9.
10. Assinger A, Laky M, Schabbauer G, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost 2011;9:799-809.
11. Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013;11: 1867-76.
12. Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014;63:872-7.
13. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27: 1038-47.
14. Karazniewicz-Lada M, Danielak D, Burchardt P, et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet 2014;53:155-64.
15. Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 2009;29:1089-102.
16. Sugidachi A, Ohno K, Ogawa T, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol 2013;169:82-9.
17. Hobl EL, Derhaschnig U, Firbas C, et al. Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor. Eur J Clin Invest 2013;43:1258-61.
18. Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007;5:82-90.
19. Hansson EC, Shams Hakimi C, Astrom-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014;112:570-5.
20. Armstrong PC, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9:552-61.
21. Kirkby NS, Leadbeater PD, Chan MV, et al. Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 2011;9:2103-5.